Literature DB >> 7248524

Studies of human pluripotential hemopoietic stem cells (CFU-GEMM) in vitro.

R C Ash, D A Detrick, E D Zanjani.   

Abstract

An in vitro clonal assay for a class of human hemopoietic progenitors (CFU-GEMM) with several characteristics of pluripotential stem cells has been previously described. In the presence of medium conditioned by leukocytes stimulated with phytohemagglutinin (PHA-LCM) and erythropoietin (Ep), CFU-GEMM give rise to mixed hemopoietic colonies containing granulocytic, erythroid, monocyte-macrophage, and megakaryocytic elements. In initial studies we found that CFU-GEMM were present in equal but low frequencies in blood (B) and bone marrow (M) mononuclear cell populations. However, when the culture system was modified by the substitution of Iscove's modified Dulbecco's medium for alpha-MEM and the addition of mercaptoethanol, a significant enhancement of mixed colony formation occurred, and an approximately 3-4-fold difference in the frequency of CFU-GEMM between B and M emerged. Replating studies showed the formation of secondary differentiated hemopoietic colonies and at least a limited capacity for self-renewal of CFU-GEMM. The in vitro growth of normal CFU-GEMM was highly dependent on hemopoietin(s) present in PHA-LCM. In vitro detection of CFU-GEMM, however, requires only relatively low permissive concentrations of Ep, in contrast to the high Ep requirement for optimal BFU-E growth in vitro. These and other data described demonstrate CFU-GEMM to be a distinct multipotential stem cell class whose assay may prove useful in the study of human blood dyscrasias.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248524

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  HLA-class II antigens on human hematopoietic progenitors.

Authors:  F W Busch; M Langer; G Pawelec; A Ziegler; P Wernet; H J Bühring; P Meyer; C Müller
Journal:  Blut       Date:  1987-03

Review 2.  Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review.

Authors:  K Leibundgut; A Hirt; A R Lüthy; A Tobler; H P Wagner
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

3.  Studies on human CFU-Mix microvolume culture by use of limiting dilution assay.

Authors:  Y Chen; B M Wang; C Y Li; D I Yu
Journal:  J Tongji Med Univ       Date:  1990

4.  Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro.

Authors:  J Brandt; N Baird; L Lu; E Srour; R Hoffman
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

5.  The role of CFU-GEMM in human hemopoiesis.

Authors:  H A Messner
Journal:  Blut       Date:  1986-10

6.  Single-stage treatment of infected tibial non-unions and osteomyelitis with bone marrow granulocytes precursors protecting bone graft.

Authors:  Philippe Hernigou; Arnaud Dubory; Yasuhiro Homma; Charles Henri Flouzat Lachaniette; Nathalie Chevallier; Helene Rouard
Journal:  Int Orthop       Date:  2017-11-13       Impact factor: 3.075

7.  Separation of immunoreactive lymphocytes from human pluripotent stem cells (CFU-GEMM) by means of counterflow centrifugation.

Authors:  T de Witte; E Koekman; E Geestman; A Plas; G Blankenborg; J Wessels; C Haanen
Journal:  Blut       Date:  1984-03

8.  Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells.

Authors:  P J Voogt; E Goulmy; W E Fibbe; W F Veenhof; A Brand; J H Falkenburg
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

9.  Scanning electron microscopic observation of CFU-mix of normal adults and leukemic patients including two cases of myeloid-lymphoid bipotent leukemia.

Authors:  Y Chen; B M Wang; C Y Li; D J Yu
Journal:  J Tongji Med Univ       Date:  1990

10.  In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera. Direct evidence of stem cell involvement.

Authors:  R C Ash; R A Detrick; E D Zanjani
Journal:  J Clin Invest       Date:  1982-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.